Alcon
Alcon is a Swiss-American eye-care company supplying ophthalmic surgical technologies, pharmaceuticals, intraocular lenses, contact lenses, and consumer eye-care products. Alcon Laboratories is a corporate name within Alcon’s eye-care business, associated with ophthalmic pharmaceuticals, surgical equipment, and vision-care products.
Last updated October 14, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Alcon is a global eye-care company focused on products and technologies used to prevent, diagnose, correct, and treat visual conditions. The company began in 1945 as a small pharmacy in Fort Worth, Texas, founded by pharmacists Robert Alexander and William Conner. Its early work centered on sterile ophthalmic products, but its scope later broadened from ophthalmic medicines into surgical devices, intraocular lenses, laser systems, contact lenses, and non-prescription eye-care products. The company became part of Nestlé in 1977. Under Nestlé ownership, Alcon expanded manufacturing in Europe and South America and increased its investment in research and development. It also entered additional product areas, including dermatology through the acquisition of Texas Pharmacal Company in 1979. Over time, ophthalmic surgery became a central part of the business, covering cataract, refractive, vitreoretinal, and glaucoma procedures. Alcon's surgical portfolio includes operating-room equipment, diagnostic and visualization systems, surgical consumables, intraocular lenses, and laser platforms. Nestlé carried out an initial public offering of part of its Alcon holding in 2002. Novartis subsequently acquired a substantial stake from Nestlé and ultimately became Alcon's controlling owner. Alcon operated within the Novartis group for several years, with its eye-care activities spanning both medical products and consumer-oriented vision care. On April 9, 2019, Novartis completed a full spin-off of Alcon, returning the company to independent public-company status. Alcon shares trade under the symbol ALC on the SIX Swiss Exchange and the New York Stock Exchange. As an independent company, Alcon is organized broadly around Surgical and Vision Care activities. Surgical products serve cataract, refractive, vitreoretinal, and glaucoma specialists, while Vision Care includes daily disposable and reusable contact lenses as well as products for dry-eye symptoms and ocular lubrication. Recognized product families include PanOptix and Clareon intraocular lenses; DAILIES TOTAL1, PRECISION1, and AIR OPTIX contact lenses; SYSTANE eye lubricants; and WaveLight laser technologies. The company also owns or has acquired businesses involved in ophthalmic pharmaceuticals and surgical innovation, including Aerie Pharmaceuticals, Ivantis, WaveLight, and, subject to announced transaction timing, LENSAR and LumiThera. Alcon sells through hospitals, ambulatory surgery centers, ophthalmologists, optometrists, optical professionals, pharmacies, and consumer channels. Its positioning combines specialist medical technology with widely distributed vision-care products. The supplied country designation of France does not match the Wikipedia subject: the Alcon described here is incorporated in Switzerland, headquartered globally in Geneva, and has a major operational base in Fort Worth, Texas. Alcon Laboratories is generally associated with Alcon’s ophthalmic business. Alcon operates across eye surgery, vision care, and related medical products, serving ophthalmologists, healthcare institutions, and vision-care consumers. Because “Alcon Laboratories” may refer to a historical company name, a legal entity, or a market-specific registration name, this entry does not treat it as a single standalone consumer brand without qualification. The supplied country was Portugal, but the identifiable corporate context is more consistent with the Alcon group headquartered in Switzerland, so that country value was not retained. The lack of a confirmed Wikipedia path, legal-entity record, and independent brand documentation means that its exact history, product portfolio, and market structure require further verification. Alcon sells through hospitals, ambulatory surgery centers, ophthalmologists, optometrists, optical professionals, pharmacies, and consumer channels. Its positioning combines professional medical technology with broadly distributed vision-care products. The name "Alcon Laboratories" is a corporate name within Alcon's eye-care business, associated with ophthalmic pharmaceuticals, surgical equipment, and vision-care products; because it may refer to a historical company name, a legal entity, or a market-specific registration name, it is not treated as a single standalone consumer brand without qualification. The supplied country for that name was Portugal, but the identifiable corporate context is more consistent with the Alcon group headquartered in Switzerland, so that country value was not retained.
History
Alcon was founded in 1945 in Fort Worth, Texas, by pharmacists Robert Alexander and William Conner. The founders initially concentrated on sterile ophthalmic products, establishing a business that served the specialized needs of eye-care professionals. The company name is derived from the surnames of its founders. Nestlé acquired Alcon in 1977. The change in ownership supported a period of international expansion, including additional manufacturing capacity in Europe and South America and increased research investment. In 1979, Alcon acquired Texas Pharmacal Company, which became Dermatological Products of Texas and later DPT Laboratories. Although the company's origins were pharmaceutical, its portfolio increasingly extended into ophthalmic surgery and devices. In 1984, Alcon established the Technical Excellence Award to recognize research and development achievements. The award became one expression of the company's emphasis on technical innovation. Alcon's activities expanded to include surgical instruments and systems, intraocular lenses, laser technologies, and products used in cataract, refractive, vitreoretinal, and other ophthalmic procedures. Its vision-care business also developed contact-lens and ocular-lubrication brands. Nestlé conducted an initial public offering of 25% of its Alcon stake in 2002. Novartis later purchased approximately 25% of Nestlé's holding in 2008 and subsequently exercised options to acquire the remaining interest. This process made Alcon part of the Novartis group, where it continued to operate as a major eye-care business with pharmaceutical, surgical, and vision-care activities. On April 9, 2019, Novartis completed the 100% spin-off of Alcon. The transaction created an independent, publicly traded company headquartered in Geneva and incorporated in the Swiss canton of Fribourg, while Fort Worth remained a major operational base. Following the separation, Alcon continued to organize its activities around Surgical and Vision Care. The Surgical business supplies technologies and consumables for procedures such as cataract surgery, refractive correction, vitreoretinal treatment, and glaucoma intervention. Vision Care includes daily disposable and reusable contact lenses and consumer products for dry-eye and ocular lubrication. In the following years, Alcon used acquisitions to add ophthalmic pharmaceutical, glaucoma, and surgical-technology capabilities. The company announced the acquisition of Ivantis in 2021, Aerie Pharmaceuticals in 2022, LENSAR in 2025, and LumiThera in 2025. Its broader group includes WaveLight, associated with laser eye-surgery technology, and Aerie Pharmaceuticals, focused on ophthalmic therapies. Alcon products are marketed through professional and consumer channels in a large number of countries, with operations reported in approximately 75 countries and products sold in more than 180. The name "Alcon Laboratories" is a corporate name within Alcon's eye-care business, associated with ophthalmic pharmaceuticals, surgical equipment, and vision-care products. Because it may refer to a historical company name, a legal entity, or a market-specific registration name, it is not treated as a single standalone consumer brand without qualification. The supplied country for that name was Portugal, but the identifiable corporate context is more consistent with the Alcon group headquartered in Switzerland, so that country value was not retained. The lack of a confirmed Wikipedia path, legal-entity record, and independent brand documentation means that its exact history, product portfolio, and market structure require further verification.
- 2025
LENSAR acquisition announced
[3]Alcon announced a planned acquisition of LENSAR and its ALLY Robotic Cataract Laser Treatment System. Alcon announced the acquisition of LumiThera and its light-based ophthalmic technologies.
- 2022
Aerie Pharmaceuticals acquisition announced
[3]Alcon agreed to acquire Aerie Pharmaceuticals to strengthen its ophthalmic pharmaceutical portfolio.
- 2021
Ivantis acquisition announced
[3]Alcon announced plans to acquire Ivantis and its glaucoma-surgery stent technology.
- 2019
Spin-off from Novartis
[2]Novartis completed the full spin-off of Alcon, creating an independent listed eye-care company.
- 2008
Novartis acquired a major stake
[3]Novartis purchased approximately 25% of Nestlé's stake and later pursued full ownership.
- 2002
Partial public offering
[3]Nestlé completed an initial public offering of 25% of its Alcon holding.
- 1984
Technical Excellence Award established
[3]Alcon created an award recognizing achievements in research and development.
- 1979
Texas Pharmacal Company acquired
[3]Alcon acquired Texas Pharmacal Company, which became Dermatological Products of Texas and later DPT Laboratories.
- 1977
Nestlé acquired Alcon
[3]Nestlé purchased Alcon and supported subsequent international manufacturing and research expansion.
- 1945
Alcon founded in Fort Worth
[1]Robert Alexander and William Conner established Alcon as a pharmacy focused on sterile ophthalmic products.
Products and positioning
A specialist global eye-care company combining professional ophthalmic surgery and pharmaceutical solutions with consumer-facing contact-lens and ocular-lubrication brands.
Intraocular lenses
PanOptix
A family of Alcon intraocular lenses used in cataract surgery. PanOptix is associated with presbyopia-correcting lens technology and is positioned within Alcon's surgical ophthalmology portfolio for postoperative vision correction.
Intraocular lenses
Clareon
An Alcon intraocular-lens platform for cataract procedures. The family forms part of the company's surgical offering and is intended for implantation during cataract surgery and subsequent visual rehabilitation.
Daily disposable contact lenses
DAILIES TOTAL1
A daily disposable contact-lens family designed for single-use vision correction. It is one of Alcon's prominent Vision Care brands and is marketed through professional optical and consumer channels.
Daily disposable contact lenses
PRECISION1
A daily disposable contact-lens line serving common vision-correction needs. The product family is positioned around convenient daily wear and is part of Alcon's broader contact-lens business.
Contact lenses
AIR OPTIX
A contact-lens brand covering reusable lenses and selected specialty designs. AIR OPTIX products extend Alcon's Vision Care presence beyond daily disposables and serve different prescription and wearing-pattern requirements.
Ocular lubrication and dry-eye care
SYSTANE
A consumer eye-care brand offering artificial tears, lubricating drops, and related products for dry-eye symptoms and ocular discomfort. SYSTANE is distributed through professional, pharmacy, and consumer channels.
Laser eye-surgery technology
WaveLight
A business and technology portfolio associated with laser systems for refractive and other ophthalmic procedures. WaveLight supports Alcon's professional surgical platform alongside its cataract and other ophthalmic technologies.
Cataract surgery laser system
ALLY Robotic Cataract Laser Treatment System
A robotic cataract laser system developed by LENSAR. Alcon announced the planned acquisition of LENSAR in 2025, with the transaction expected to expand its cataract-surgery technology portfolio.
医疗器械与手术耗材
Ophthalmic surgical products
One of Alcon's major business areas, serving cataract, refractive, and other ophthalmic procedures with equipment, instruments, and related consumables. The products specifically sold under the Alcon Laboratories name require market- and entity-level verification.
视力护理
Contact lenses and vision care
Alcon's vision-care business includes contact lenses and related care products for routine vision correction and eye-care needs. The exact relationship between this product line and the Alcon Laboratories name has not been fully confirmed.
Brand decisions
2025
Acquire LENSARM&ABackground
Alcon sought to add robotic cataract-laser technology through LENSAR and its ALLY system.
Action taken
Alcon announced a $356 million acquisition, with closing expected in the second half of 2025 according to the reference material.
Announced transaction value. $356 million (2025 announcement)
2022
Acquire Aerie PharmaceuticalsM&ABackground
Alcon aimed to enhance its ophthalmic pharmaceutical portfolio, including therapies for glaucoma and other eye diseases.
Action taken
Alcon agreed to acquire Aerie Pharmaceuticals for $770 million.
Announced transaction value. $770 million (2022 announcement)
2021
Acquire IvantisM&ABackground
Alcon sought to broaden its glaucoma-surgery capabilities through Ivantis and its stent technology.
Action taken
Alcon announced an agreement to acquire Ivantis for at least $475 million.
Announced transaction value. $475 million or more (2021 announcement)
2019
Separate from Novartis and operate as an independent companyStrategyBackground
Novartis had owned Alcon as part of its healthcare portfolio after acquiring control from Nestlé. The separation was intended to create an independent, focused eye-care company.
Action taken
Novartis completed the 100% spin-off of Alcon on April 9, 2019, and Alcon became independently listed.
Aftermath
Alcon continued with separate Surgical and Vision Care businesses and shares traded under ALC on the SIX Swiss Exchange and New York Stock Exchange.
Recent events
Alcon acquires Neurotech Pharmaceuticals[6]
Reported:
Alcon announced that it had acquired Neurotech Pharmaceuticals for $550 million, with possible additional contingent payments tied to commercial milestones.
Alcon completes acquisition of Ivantis[7]
Reported:
Alcon completed its acquisition of Ivantis, gaining rights to the Hydrus microstent.
Alcon introduces UV-filtering PanOptix and Vivity lenses in Canada[8]
Reported:
Alcon announced the availability in Canada of four UV-filtering intraocular lenses: AcrySof IQ PanOptix UV, PanOptix Toric UV, Vivity UV and Vivity Toric UV. The lenses were added to Alcon's presbyopia-correcting lens portfolio.
CorNeat Vision and LiveU implement remote surgeon training with Alcon[9]
Reported:
CorNeat Vision and LiveU announced a partnership and successful implementation of an on-demand Remote Surgeon Virtual Presence solution, working with Alcon's NGENUITY 3D Visualization System to train Canadian cornea experts remotely from Israel.
Pataday Extra Strength becomes available through U.S. retailers[10]
Reported:
Alcon announced that Pataday Once Daily Relief Extra Strength was available in-store and online at U.S. retailers following its 2020 FDA approval for over-the-counter sale. The product was available in select stores and through online retailers, with wider availability planned to begin that month.
Alcon expands nationwide availability of Clareon IOL with AutonoMe in Canada[11]
Reported:
Alcon announced the nationwide launch in Canada of the Clareon intraocular lens with the AutonoMe delivery system, expanding availability after an earlier introduction to a select group of Canadian ophthalmologists.
Alcon launches PRECISION1 contact lenses in Canada[12]
Reported:
Alcon launched PRECISION1 daily disposable silicone hydrogel contact lenses in Canada. Distribution to optometrists had started, with wider availability planned for fall 2020.
FDA approves Pataday products for over-the-counter use[13]
Reported:
The FDA approved Alcon's Pataday Once Daily Relief and Pataday Twice Daily Relief products for over-the-counter use.
Alcon announces planned U.S. retail availability for Pataday OTC products[13]
Reported:
Alcon said Pataday Once Daily Relief and Pataday Twice Daily Relief would become commercially available in the United States beginning March 2, 2020, through major drug, food and mass-market retailers. The source reports a plan, not that retail availability had already begun.
Sources15 sources
- 1Alcon official historyalcon.com
- 2Alcon official corporate informationalcon.com
- 3Alconen.wikipedia.org
- 4Alcon official websitealcon.com
- 5https://www.alcon.comalcon.com
- 6Alcon 收购 Neurotech Pharmaceuticalsfinanznachrichten.de
- 7Alcon完成对Ivantis的收购healio.com
- 8Alcon 在加拿大推出具紫外线过滤功能的 PanOptix 和 Vivity 人工晶状体newswire.ca
- 9CorNeat Vision与LiveU携手Alcon实施远程外科医生培训prnewswire.com
- 10Pataday Extra Strength 在美国零售渠道上市finanznachrichten.de
- 11Alcon在加拿大扩大Clareon人工晶状体与AutonoMe系统的全国供应newswire.ca
- 12爱尔康在加拿大推出PRECISION1隐形眼镜newswire.ca
- 13FDA批准Pataday产品转为非处方药healio.com
- 14Alcon Acquires Neurotech Pharmaceuticals for $550M - Orange County Business Journalocbj.com
- 15Alcon Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strengthfinanznachrichten.de
Cite this profile: Cite the canonical profile. /brand-wiki/alcon · Editorial policy · How profiles are compiled